FTC Reaches Settlement With Corteva
By Connor Hart
The Federal Trade Commission reached a settlement agreement with Corteva, aiming to lower pesticide prices for farmers by ensuring greater access to generic products.
The settlement resolves a lawsuit brought by the FTC and a coalition of state attorneys general in 2022, which alleged Corteva used rebate programs to block competitors from selling cheaper generic insecticides and other chemicals to farmers.
According to the suit, Corteva, a U.S.-based seed and pesticide maker, offered discounts to distributors, as long as the distributors limited their purchases of competing generic pesticides to below a certain threshold. As a result, the suit alleged, farmers' costs have been inflated by hundreds of millions of dollars a year.
Under the terms of the settlement, Corteva will dismantle its existing pesticides loyalty program, the FTC said. The company will also pay $35 million, resolving claims with California, Colorado, Illinois, Indiana, Iowa, Minnesota, Nebraska, Oregon, Tennessee, Texas, Washington and Wisconsin.
The order additionally prohibits the company from conditioning payments or other benefits to a distributor, as long as that firm purchases a high share of a given pesticide active ingredient from Corteva or similarly limits its purchases of generic equivalents, for a period of 10 years.
"We're pleased to reach a resolution in the FTC matter and continue to focus on our business, our customers and our work: delivering groundbreaking innovation and agronomic support to retailers and farmers around the world," a Corteva spokesperson said.
The settlement announced only resolves the claims against Corteva. The FTC also in 2022 accused Syngenta Group, a Swiss seed and pesticide maker, of artificially inflating prices for farmers. Litigation against Syngenta remains ongoing, the agency said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
September 28, 2026 11:08 ET (15:08 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
